BevacizumabIn First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma

被引：0
|
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Vascular Endothelial Growth Factor; Renal Cell Carcinoma; Bevacizumab; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Bevacizumab, an anti-vascular endothelial growth factor recombinant humanized monoclonal antibody, directly inhibits tumor angiogenesis and hence tumor growth.
引用
收藏
页码：113 / 120
页数：7
相关论文
共 50 条
  • [21] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [22] Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
    Javier Puente
    Xavier García del Muro
    Álvaro Pinto
    Nuria Láinez
    Emilio Esteban
    José Ángel Arranz
    Enrique Gallardo
    María José Méndez
    Pablo Maroto
    Enrique Grande
    Cristina Suárez
    Targeted Oncology, 2016, 11 : 129 - 141
  • [23] Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
    Christensen, Bryce R.
    Hajja, Yasmin M.
    Koshkin, Vadim
    Barata, Pedro C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (02)
  • [24] First-Line Therapy of Metastatic Renal Cell Carcinoma - Update 2009
    Miller, Kurt
    ONKOLOGIE, 2010, 33 : 5 - 9
  • [25] Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
    Chen, Yu-Wei
    Rini, Brian, I
    CURRENT ONCOLOGY REPORTS, 2022, 24 (06) : 695 - 702
  • [26] Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Nishihara, Kiyoaki
    Ogasawara, Naoyuki
    Kurose, Hirofumi
    Hayashi, Shuichiro
    Chikui, Katsuaki
    Suyama, Shunsuke
    Nakiri, Makoto
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2015, 35 (06) : 3415 - 3421
  • [27] Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma
    Bryce R. Christensen
    Yasmin M. Hajja
    Vadim Koshkin
    Pedro C. Barata
    Current Treatment Options in Oncology, 2021, 22
  • [28] Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma
    Chen, Chi-Chang
    Hess, Gregory P.
    Liu, Zhimei
    Gesme, Dean H.
    Agarwala, Sanjiv S.
    Garay, Carlos C.
    Hill, Jerrold W.
    Guo, Amy
    CLINICAL GENITOURINARY CANCER, 2012, 10 (04) : 256 - 261
  • [29] Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
    Villa, Guillermo
    Hernandez-Pastor, Luis-Javier
    BMC CANCER, 2013, 13
  • [30] Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma
    Brian I. Rini
    Victor Gruenwald
    Eric Jonasch
    Mayer N. Fishman
    Yoshihiko Tomita
    M. Dror Michaelson
    Jamal Tarazi
    Laura Cisar
    Subramanian Hariharan
    Angel H. Bair
    Brad Rosbrook
    Thomas E. Hutson
    Targeted Oncology, 2017, 12 : 333 - 340
12345